Clinical trials: Chimeric Antigen Receptor T-cell Therapy
Diffuse Large B Cell Lymphoma
An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection
This is a single-arm, open-label, dose escalation, phase I study, aiming to evaluate the safety and efficacy of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific Chimeric Antigen Receptor (CAR) T-cells in patient with…
- Trial name
- NCT04486872
- Testing
- Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Metastatic Tumor, Advanced Solid Tumor
A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CD70-positive advanced/metastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.
- Conditions
- Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer
- Trial name
- NCT05420545
- Testing
- CD70 CAR-T cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Acute Myeloid Leukemia (AML)
Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
This single-arm, open-label phase I trial evaluates the safety and tolerability of ICG415, autologous CAR-T cells targeting CD33 and CLL1, in patients with relapsed or refractory acute myeloid leukemia (AML).
- Trial name
- ICG415-AML-01 (NCT07668557)
- Testing
- Anti-CD33-CLL1 CAR-T cells (ICG415) following lymphodepleting fludarabine and cyclophosphamide
- Where
- 2 sites in China
- Volunteers
- 18 people
- Sponsor
- iCell Gene Therapeutics
Non-Hodgkin Lymphoma
Development of Prognostic Models for Response and Toxicity to CAR-T Cell Therapy in Patients with Relapsed/refractory Non Hodgkin's Lymphoma.
Observational, single-center, tissue-based cohort study involving both retrospective and prospective enrollment of patients undergoing CAR-T cell therapy and up to 1 year of prospective follow-up necessary to detect the outcomes…
- Trial name
- CLIO (NCT06720701)
- Where
- Italy
- Volunteers
- 125 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
CD 19+ Acute Leukemia
Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia
Patients with relapsed or refractory CD 19+ leukemia who have achieved remission after CD19 CAR-T cell treatment sometimes relapse because the CD 19 CAR-T cells decrease in number over time.
- Trial name
- NCT03186118
- Testing
- T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Seattle Children's Hospital
Acute Lymphoblastic Leukemia
Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia
This early phase I trial tests the safety and side effects of allogeneic CMV-specific CD19-CAR T cells plus CMV-MVA vaccine and how well it works in treating patients with high-risk acute lymphoblastic leukemia after a matched…
- Trial name
- NCT06735690
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Anti-CD19-CAR CMV-specific T-lymphocytes, Biospecimen Collection
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
B Cell Lymphoma, B Cell Leukemia
CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.
Chimeric antigen receptor (CAR) T cells targeting CD19 will be evaluated for safety and efficacy in patients with B cell lymphoma or leukemia.
- Trial name
- NCT02132624
- Testing
- Autologous 3rd generation CD19-targeting CAR T cells
- Where
- Sweden
- Volunteers
- 15 people
- Sponsor
- Uppsala University
AIHA - Warm Autoimmune Hemolytic Anemia, UCART
UCAR T-cell Therapy Targeting CD19/BCMA in Relapsed/Refractory Autoimmune Hemolytic Anemia
This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in AIHA who have failed ≥ 3 lines of therapy
- Trial name
- NCT07530380
- Testing
- QT-219C Cell Injection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The Second Hospital of Anhui Medical University
Non-Hodgkin Lymphoma, B-cell Non-Hodgkin Lymphoma (B-NHL)
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
This open-label, single arm phase 1 trial aims to determine the safety and tolerability of anti-CD19 and anti-CD22 chimeric antigen receptor-expressing (CAR) T cells (CD19x22 CAR T) in adolescents and adults with…
- Conditions
- Non-Hodgkin Lymphoma, B-cell Non-Hodgkin Lymphoma (B-NHL), Mantle Cell Lymphoma (MCL), CNS Lymphoma
- Trial name
- NCT05098613
- Testing
- CD19x22 CAR T Cells
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Colorado, Denver
B-NHL, B-Non Hodgkin Lymphoma
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Background: Acute lymphoblastic leukemia (ALL) is the most common cancer in children. About 90% of children and young adults who are treated for ALL can now be cured.
- Conditions
- B-NHL, B-Non Hodgkin Lymphoma, Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT05442515
- Testing
- CD19/CD22-CAR-transduced T cells, cyclophosphamide, fludarabine
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Hematologic Malignancy
Identifying Cellular and Molecular Determinants of Efficacy and Resistance in Patients Undergoing CAR-T Therapy
In recent years we have witnessed a breakthrough in the treatment of leukemia and lymphoma using autologous CAR-T cells that can induce durable remission in patients.
- Trial name
- CAR-Lille (NCT07609485)
- Where
- 2 sites in France
- Volunteers
- 700 people
- Sponsor
- University Hospital, Lille
Multiple Myeloma
A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma
This is a single-arm, open-label, dose-escalation study to evaluate the safety, tolerability, cellular kinetics and initial efficacy of CAR-T cell therapy targeting GPRC5D in multiple myeloma subjects who have failed the standard…
- Trial name
- NCT05016778
- Testing
- GPRC5D-CAR-T
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Zhejiang University
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma
The purpose of this study is to test the safety and efficacy of AUTO3, a CAR T cell treatment targeting CD19 and CD22 with consolidation or pre-conditioning with anti-PD1 antibody in patients with DLBCL
- Trial name
- ALEXANDER (NCT03287817)
- Testing
- AUTO3
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 52 people
- Sponsor
- Autolus Limited
Rejection; Transplant, Liver, Liver Failure
Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients
The purpose of this study is to evaluate the safety and tolerability of QEL-001 in the prevention of liver transplant rejection following immunosuppression withdrawal.
- Conditions
- Rejection; Transplant, Liver, Liver Failure, Liver Diseases
- Trial name
- LIBERATE (NCT05234190)
- Testing
- QEL-001
- Where
- 10 sites in Belgium, Spain and 1 more
- Volunteers
- 33 people
- Sponsor
- Quell Therapeutics Limited
B-cell Non-Hodgkin's Lymphoma
CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.
This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of CD19/CD20 Dual-CAR-T cells in patients with refractory or relapsed B-NHL.
- Trial name
- NCT04697290
- Testing
- CD19/CD20 Dual-CAR-T cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Acute Lymphoblastic Leukemia
Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
Traditional standard treatments of B cell acute lymphoblastic leukemia is not perfect for fighting cancer. Many people do not respond to the standard treatments of ALL.
- Trial name
- NCT02186860
- Testing
- CAR-T cells
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
B-cell Acute Lymphoblastic Leukemia
CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
This is a single center, single arm, open-lable phase 1 study to determine the safety and efficacy of CD19-CAR-T cells in patients with relapsed or refractory acute B-cell lymphoblastic leukemia (R/R B-ALL).
- Trial name
- NCT03671460
- Testing
- CD19 CAR-T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Tianjin Mycure Medical Technology Co., Ltd
T-cell Leukemia, T-cell Lymphoma
Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies
The prognosis of patients with relapsed and/or refractory T-cell hematologic malignancies is poor due to lacking sufficient treatment.Anti-CD(cluster of differentiation antigen)19 CAR(chimeric antigen receptor)-T cell therapies…
- Trial name
- NCT04264078
- Testing
- CD7 UCAR-T cells, Fludarabine, Cytoxan
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Xinqiao Hospital of Chongqing
Relapsed and Refractory, Lymphoid Hematological Malignancies
Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma
Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma
- Trial name
- NCT04626908
- Testing
- GC022F CAR-T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- He Huang
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
A Study of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphocytic Leukaemia Refractory
- Trial name
- NCT04603872
- Testing
- CD19/BCMA Targeted CAR T-cells and dasatinib, CD19/BCMA Targeted CAR T-cells
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhejiang University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.